ATE377009T1 - Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum - Google Patents

Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum

Info

Publication number
ATE377009T1
ATE377009T1 AT02772689T AT02772689T ATE377009T1 AT E377009 T1 ATE377009 T1 AT E377009T1 AT 02772689 T AT02772689 T AT 02772689T AT 02772689 T AT02772689 T AT 02772689T AT E377009 T1 ATE377009 T1 AT E377009T1
Authority
AT
Austria
Prior art keywords
cell growth
abnormal cell
substituted bicyclic
treating abnormal
producing substituted
Prior art date
Application number
AT02772689T
Other languages
English (en)
Inventor
David Ripin
Original Assignee
Osi Pharm Inc
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc, Pfizer filed Critical Osi Pharm Inc
Application granted granted Critical
Publication of ATE377009T1 publication Critical patent/ATE377009T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
AT02772689T 2001-11-30 2002-10-03 Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum ATE377009T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33464701P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
ATE377009T1 true ATE377009T1 (de) 2007-11-15

Family

ID=23308141

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02772689T ATE377009T1 (de) 2001-11-30 2002-10-03 Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum

Country Status (28)

Country Link
US (1) US20030144506A1 (de)
EP (1) EP1448551B1 (de)
JP (1) JP4220388B2 (de)
KR (1) KR20040054813A (de)
CN (1) CN1639149A (de)
AR (1) AR037591A1 (de)
AT (1) ATE377009T1 (de)
AU (1) AU2002337428A1 (de)
BR (1) BR0214606A (de)
CA (1) CA2462149C (de)
DE (1) DE60223279T2 (de)
DO (1) DOP2002000519A (de)
ES (1) ES2295409T3 (de)
GT (1) GT200200245A (de)
HN (1) HN2002000334A (de)
HU (1) HUP0500117A3 (de)
IL (1) IL160971A0 (de)
MX (1) MXPA04005157A (de)
PA (1) PA8558601A1 (de)
PE (1) PE20030643A1 (de)
PL (1) PL370911A1 (de)
RS (1) RS44004A (de)
RU (1) RU2004116345A (de)
SV (1) SV2004001419A (de)
TN (1) TNSN02096A1 (de)
TW (1) TW200300691A (de)
WO (1) WO2003045939A1 (de)
ZA (1) ZA200402054B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2510323A1 (en) * 2002-12-18 2004-07-01 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
AU2003283743A1 (en) * 2002-12-19 2004-07-14 Pfizer Products Inc. Complexes of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
MXPA05008810A (es) * 2003-04-09 2005-10-18 Pfizer Prod Inc Procedimientos para preparar derivados biciclicos sustituidos.
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2005003100A2 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
EP1746999B1 (de) * 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-chinazolin-6-yl-amide
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
RU2400369C2 (ru) * 2005-12-02 2010-09-27 Дзе Пэйпер Продактс Лимитед Голографический гибкий тубный ламинат для упаковки и способ его изготовления
JP2022502495A (ja) 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (de) * 1994-11-12 1997-12-01 Zeneca Ltd
DE19501481A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CA2413424C (en) * 2000-06-22 2007-10-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
ES2295409T3 (es) 2008-04-16
JP2005515986A (ja) 2005-06-02
HN2002000334A (es) 2003-02-21
PA8558601A1 (es) 2003-06-30
PE20030643A1 (es) 2003-07-23
AR037591A1 (es) 2004-11-17
RS44004A (en) 2006-10-27
TNSN02096A1 (en) 2005-12-23
KR20040054813A (ko) 2004-06-25
HUP0500117A3 (en) 2008-03-28
CN1639149A (zh) 2005-07-13
DE60223279D1 (de) 2007-12-13
BR0214606A (pt) 2004-09-14
JP4220388B2 (ja) 2009-02-04
TW200300691A (en) 2003-06-16
SV2004001419A (es) 2004-02-24
EP1448551B1 (de) 2007-10-31
CA2462149A1 (en) 2003-06-05
IL160971A0 (en) 2004-08-31
CA2462149C (en) 2010-06-22
EP1448551A1 (de) 2004-08-25
HUP0500117A2 (hu) 2005-05-30
WO2003045939A1 (en) 2003-06-05
ZA200402054B (en) 2005-05-23
GT200200245A (es) 2003-09-24
MXPA04005157A (es) 2004-08-11
AU2002337428A1 (en) 2003-06-10
DE60223279T2 (de) 2008-05-29
US20030144506A1 (en) 2003-07-31
PL370911A1 (en) 2005-05-30
RU2004116345A (ru) 2005-03-27
DOP2002000519A (es) 2003-05-31

Similar Documents

Publication Publication Date Title
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
DE60220646D1 (de) Verfahren zur herstellung von verbindungsprofilen
DE60221399D1 (de) Verfahren zur herstellung von mitteldistillaten
DE60224643D1 (de) Verfahren zur herstellung von reifen
ATE403641T1 (de) Verfahren zur herstellung von o- desmethylvenlafaxin
ATE515500T1 (de) Verfahren zur herstellung von telmisartan
ATE453648T1 (de) Verfahren zur herstellung von hexahydrofuroc2,3- büfuran-3-ol
ATE382631T1 (de) Verfahren zur herstellung von virusinaktiviertem humanem gammaglobulin g
ATE286011T1 (de) Verfahren zur herstellung von 1-octen
ATE414077T1 (de) Verfahren zur herstellung von 1-ä(benzimidazol-1- yl)chinolin-8-ylüpiperidin-4-ylaminderivaten
DE60230908D1 (de) Verfahren zur herstellung von polyarylenethern
DE60304828D1 (de) Verfahren zur herstellung von nanopartikeln von block-copolymeren
DE60225539D1 (de) Verfahren zur kontinuierlichen herstellung von polyarylensulfid
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
ATE377009T1 (de) Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum
DE502004005626D1 (de) Verfahren zur herstellung von organoacylphosphiten
ATE455778T1 (de) Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat
DE60202755D1 (de) Verfahren zur herstellung von imidazolverbindungen
DE60204334D1 (de) Verfahren zur herstellung von repaglinide
ATE316959T1 (de) Verfahren zur herstellung von 2- halogenpyridincarbonsäureamiden
ATE441662T1 (de) Verfahren zur herstellung von echinocandinderivaten
ATE553103T1 (de) Verfahren zur herstellung von (s)-pantoprazol
DE50303611D1 (de) Verfahren zur herstellung von polyisobuten
ATE273315T1 (de) Verfahren zur herstellung von n- phosphonomethyliminodiessigsäure
DE50312095D1 (de) Verfahren zur herstellung hochfester polypropylenfasern

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties